Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M23-721 phase 2/3 trial of livmoniplimab + budigalimab + chemotherapy versus pembrolizumab + chemotherapy in previously untreated metastatic nonsquamous NSCLC
MOH_2024-02-07_013246Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of livmoniplimab and budigalimab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by AbbVie Inc. Started Jan 2024; status: recruiting.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-02-07_013246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-07_013246.